Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer.

Curr Oncol · 2025 · PMC12839656 · PMID 41590322

Europe PMC DOI

hedged sentences

0.1190

closest p · 2.4× alpha

0.1190

boldest claim

The sentences

did not reach statistical significancep = 0.119not close (p > 0.1)

13.5 months), while this difference did not reach statistical significance ( p = 0.119) ( Figure 3 D).

also in 111,027 other papers

showed a trendno p-value reported

Furthermore, patients with only a single metastatic site showed a trend toward improved overall survival in comparison to those with multiple metastatic sites (19.0 vs. 13.5 months), while this difference did not reach statistical significance ( p = 0.119) ( Figure 3 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.